Luca Vignatelli1,2, Francesca Bisulli3,4, Giada Giovannini5, Laura Licchetta3,4, Ilaria Naldi4, Barbara Mostacci3, Guido Rubboli3,6,7, Federica Provini3,4, Paolo Tinuper3,4, Stefano Meletti5. 1. Department of Primary Care, Local Health Trust, Bologna, Italy. 2. Health and Social Regional Agency, Emilia-Romagna Region, Bologna, Italy. 3. IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy. 4. Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy. 5. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, NOCSAE Hospital, Local Health Trust, Modena, Italy. 6. Danish Epilepsy Center, Epilepsihospitalet, Dianalund, Denmark. 7. Institute of Clinical Medicine, University of Copenhagen, Denmark.
Abstract
STUDY OBJECTIVES: To estimate the prevalence of nocturnal frontal lobe epilepsy (NFLE) in the adults of two areas of the Emilia-Romagna region (northeast Italy) and to describe the clinical features from a population-based perspective. DESIGN: Population-based retrospective cohort study including adults with NFLE. SETTING: Two areas of the Emilia-Romagna region: the city of Bologna (330,901 adult residents) and five districts of the province of Modena (424,007). Prevalence day: December 31, 2010. PARTICIPANTS: Patients with NFLE collected from multiple databases of neurologic hub centers of the districts involved. Diagnostic criteria: clinical history of sleep related bizarre motor attacks and videopolysomnographic recording confirming the typical features of NFLE. Inclusion criteria for prevalence calculation: residence in one of the two geographic areas on the prevalence day and an "active" or "in remission with treatment" form of NFLE. MEASUREMENTS AND RESULTS: Six subjects from Bologna and eight from Modena were included. Crude prevalence (per 100,000 residents) was 1.8 (95% confidence interval 0.7-4.0) in Bologna and 1.9 (0.8-3.7) in Modena. Similarly, the main clinical features were consistent: onset during adolescence (median age 11-13 y), mainly hyperkinetic seizures, nonlesional form in more than two-thirds of cases, an active form of epilepsy in more than two-thirds of cases. A family history of epilepsy was reported only for two patients. CONCLUSIONS: This epidemiologic study establishes that NFLE is a rare epileptic condition, fulfilling the definition for rare disease. Because of methodological limitations of our case ascertainment, the estimates we disclose must be considered the minimum prevalence.
STUDY OBJECTIVES: To estimate the prevalence of nocturnal frontal lobe epilepsy (NFLE) in the adults of two areas of the Emilia-Romagna region (northeast Italy) and to describe the clinical features from a population-based perspective. DESIGN: Population-based retrospective cohort study including adults with NFLE. SETTING: Two areas of the Emilia-Romagna region: the city of Bologna (330,901 adult residents) and five districts of the province of Modena (424,007). Prevalence day: December 31, 2010. PARTICIPANTS: Patients with NFLE collected from multiple databases of neurologic hub centers of the districts involved. Diagnostic criteria: clinical history of sleep related bizarre motor attacks and videopolysomnographic recording confirming the typical features of NFLE. Inclusion criteria for prevalence calculation: residence in one of the two geographic areas on the prevalence day and an "active" or "in remission with treatment" form of NFLE. MEASUREMENTS AND RESULTS: Six subjects from Bologna and eight from Modena were included. Crude prevalence (per 100,000 residents) was 1.8 (95% confidence interval 0.7-4.0) in Bologna and 1.9 (0.8-3.7) in Modena. Similarly, the main clinical features were consistent: onset during adolescence (median age 11-13 y), mainly hyperkinetic seizures, nonlesional form in more than two-thirds of cases, an active form of epilepsy in more than two-thirds of cases. A family history of epilepsy was reported only for two patients. CONCLUSIONS: This epidemiologic study establishes that NFLE is a rare epileptic condition, fulfilling the definition for rare disease. Because of methodological limitations of our case ascertainment, the estimates we disclose must be considered the minimum prevalence.
Authors: F Picard; S Baulac; P Kahane; E Hirsch; R Sebastianelli; P Thomas; F Vigevano; P Genton; R Guerrini; C A Gericke; I An; G Rudolf; A Herman; A Brice; C Marescaux; E LeGuern Journal: Brain Date: 2000-06 Impact factor: 13.501
Authors: Saeko Ishida; Fabienne Picard; Gabrielle Rudolf; Eric Noé; Guillaume Achaz; Pierre Thomas; Pierre Genton; Emeline Mundwiller; Markus Wolff; Christian Marescaux; Richard Miles; Michel Baulac; Edouard Hirsch; Eric Leguern; Stéphanie Baulac Journal: Nat Genet Date: 2013-03-31 Impact factor: 38.330
Authors: A Oldani; M Zucconi; R Asselta; M Modugno; M T Bonati; L Dalprà; M Malcovati; M L Tenchini; S Smirne; L Ferini-Strambi Journal: Brain Date: 1998-02 Impact factor: 13.501
Authors: I E Scheffer; K P Bhatia; I Lopes-Cendes; D R Fish; C D Marsden; E Andermann; F Andermann; R Desbiens; D Keene; F Cendes Journal: Brain Date: 1995-02 Impact factor: 13.501
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Paolo Tinuper; Francesca Bisulli; J H Cross; Dale Hesdorffer; Philippe Kahane; Lino Nobili; Federica Provini; Ingrid E Scheffer; Laura Tassi; Luca Vignatelli; Claudio Bassetti; Fabio Cirignotta; Christopher Derry; Antonio Gambardella; Renzo Guerrini; Peter Halasz; Laura Licchetta; Mark Mahowald; Raffaele Manni; Carla Marini; Barbara Mostacci; Ilaria Naldi; Liborio Parrino; Fabienne Picard; Maura Pugliatti; Philippe Ryvlin; Federico Vigevano; Marco Zucconi; Samuel Berkovic; Ruth Ottman Journal: Neurology Date: 2016-04-15 Impact factor: 9.910
Authors: Stefania Evangelisti; Claudia Testa; Lorenzo Ferri; Laura Ludovica Gramegna; David Neil Manners; Giovanni Rizzo; Daniel Remondini; Gastone Castellani; Ilaria Naldi; Francesca Bisulli; Caterina Tonon; Paolo Tinuper; Raffaele Lodi Journal: Neuroimage Clin Date: 2017-12-06 Impact factor: 4.881